Mixed feelings.
Lot's of 'we are bullish' statements, but very scant on actual expectations of FY 2025 figures.
Probably the most important takeaways for me:
No current purchasers of Febridex in Australia
Good expansion of Febridex into the USA Student health market
Progress made on CLIA waiver
Progress made on re-imbursement coding - why that wasn't done before launch is baffling tbh.
I think it all depends on the Febridex uptake in the next FY (obviously) to see whether we will be 100% reliant on IP deals to keep the doors open.
If it takes off - so will the SP. It's that simple.
Overall - 6.5/10
Lots of bones, not too much meat.
Add to My Watchlist
What is My Watchlist?
